References in periodicals archive ?
Neem leaf glycoprotein enhances carcinoembryonic antigen presentation of dendritic cells to T and B cells for induction of antitumor immunity by allowing generation of immune effector / memory response.
Keywords: cancer, breast cancer, carcinoembryonic antigen, alpha-fetoprotein, CEA, AFP, CA 15-3, CA 27.
2] Nonstandard abbreviations: CA125, cancer antigen 125; PSA, prostate-specific antigen; CEA, carcinoembryonic antigen.
The tumors also demonstrated a consistent immunohistochemical staining profile, with expression of epithelial membrane antigen (EMA), cytokeratin (CK) 17, high-molecular-weight keratins, and in some cases, focal positivity of carcinoembryonic antigen.
Immunohistochemical staining of tumour tissue was negative for prostate-specific antigen (PSA) and prostate-specific acid phosphatase, strongly positive for cytokeratin (CK) 7/20/ carcinoembryonic antigen (CEA), strong nuclear positive for caudal-related homeobox 2 (CDX2) and negative staining for CK5/6.
Patients were followed with office examination and laboratory evaluation including carcinoembryonic antigen as well as CT scans every 3 months for 2 years or until recurrence.
Follow-up fell short in 74% of survivors, with the greatest lapse seen in carcinoembryonic antigen (CEA) testing, which is done to detect recurrent colon cancer.
Immunohistochemical staining can be an important diagnostic aid in these cases; columnar cell variants of PTC should be negative for carcinoembryonic antigen and positive for thyroglobulin unless the cells are too poorly differentiated.
Results of testing for tumor-associated antigens, such as carcinoembryonic antigen, carcinoma antigen 19-9, prostatic specific antigen, and alpha fetoprotein, were negative.
The appearance of symptoms was concurrent with the elevation of carcinoembryonic antigen in our case.
The Court held that Immunomedics' Dutch patent for highly specific monoclonal antibodies against the cancer marker, carcinoembryonic antigen (CEA), was valid.
SEATTLE -- Etubics Corporation, a biopharmaceutical company developing "next generation" vector vaccines, has entered into Phase I trials at Duke University with its ETBX-011, a therapeutic vaccine candidate that is intended to treat Carcinoembryonic Antigen (CEA)-expressing cancers such as colorectal cancer.